MUVON Therapeutics Reports Positive Phase 2 Results for its First-in-Class Muscle Precursor Cell (MPC)-based Tissue-Engineered Therapy Showing Clinically Meaningful and Statistically Significant Benefits in Stress Urinary Incontinence
Zurich, Switzerland, December 03, 2025 – MUVON Therapeutics AG, a clinical-stage biotechnology company, reports positive topline results from the Phase 2 clinical trial SUISSE-MPC2 (NCT05534269) evaluating its novel proprietary muscle precursor cell (MPC)-based tissue-engineered therapy platform in female stress urinary incontinence (SUI). The study met both its primary and secondary endpoints (p<0.0001), demonstrating significant, clinically […]